Flies as the ointment : Drosophila modeling to enhance drug discovery

Fly

Volumn 3, Issue 1, 2009, Pages 39-49

  Bell, Aaron J ^a   McBride, Sean M J ^a   Dockendorff, Thomas C ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Disease modeling; Drosophila; Drug discovery; Mental retardation; Neurodegeneration

Indexed keywords

ANIMALIA; INVERTEBRATA; MAMMALIA;

EID: 69249130978     PISSN: 19336934     EISSN: 19336942     Source Type: Journal    
DOI: 10.4161/fly.3.1.7774     Document Type: Review

References (123)

1. Miklos GL, Rubin GM. The role of the genome project in determining gene function: insights from model organisms. Cell 1996; 86: 521-529.
2. Siomi MC, Siomi H, Sauer WH, Srinivasan S, Nussbaum RL, Dreyfuss G. FXR1, an autosomal homolog of the fragile X mental retardation gene. EMBO J 1995; 14: 2401-2418.
3. Zhang Y, O'Connor JP, Siomi MC, Srinivasan S, Dutra A, Nussbaum RL, Dreyfuss G. The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO J 1995; 14: 5358-5366.
4. Gould EL, Loesch DZ, Martin MJ, Hagerman RJ, Armstrong SM, Huggins RM. Melatonin profiles and sleep characteristics in boys with fragile X syndrome: a preliminary study. Am J Med Genet 2000; 95: 307-15.
5. Dockendorff TC, Su HS, McBride SM, Yang Z, Choi CH, Siwicki KK, et al. Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 2002; 34: 973-984.
6. Morales J, Hiesinger PR, Schroeder AJ, Kume K, Verstreken P, Jackson FR, et al. Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron 2002; 34: 961-972.
7. Zhang J, Fang Z, Jud C, Vansteensel MJ, Kaasik K, Lee CC, Albrecht U, et al. Fragile X-related proteins regulate mammalian circadian behavioral rhythms. Am J Hum Genet 2008; 83: 43-52.
8. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27: 370-377.
9. Chang S, Bray SM, Li Z, Zarnescu DC, He C, Jin P, Warren ST. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 2008; 4: 256-63.
10. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 1999; 285: 901-906.
11. Bellen HJ, Levis RW, Liao G, He Y, Carlson JW, Tsang G, Evans-Holm M, et al. The BDGP gene disruption project: single transposon insertions associated with 40% of Drosophila genes. Genetics 2004 167: 761-781.
12. Collins FS, Rossant J, Wurst W. A mouse for all reasons. Cell 2007; 128: 9-13.
13. Spradling AC, Rubin GM. Transposition of cloned P elements into Drosophila germ line chromosomes. Science 1982; 218: 341-347.
14. Rubin GM, Spradling AC. Genetic transformation of Drosophila with transposable element vectors. Science 1982; 218: 348-53.
15. Bateman JR, Lee AM, Wu CT. Site-specific transformation of Drosophila via phiC31 integrase-mediated cassette exchange. Genetics 2006; 173: 769-777.
16. Venken KJ, He Y, Hoskins RA, Bellen HJ. P[acman]: a BAC transgenic platform for targeted insertion of large DNA fragments in D. melanogaster. Science 2006; 314: 1747-1751.
17. Venken KJ, Bellen HJ. Transgenesis upgrades for Drosophila melanogaster. Development 2007; 134: 3571-3584.
18. Groth AC, Fish M, Nusse R, Calos MP. Construction of transgenic Drosophila by using the site-specific integrase from phage phiC31. Genetics 2004; 166: 1775-1782.
19. Rong YS, Golic KG. Gene targeting by homologous recombination in Drosophila. Science 2000; 288: 2013-2018.
20. Rong YS, Titen SW, Xie HB, Golic MM, Bastiani M, Bandyopadhyay P, et al. Targeted mutagenesis by homologous recombination in D. melanogaster. Genes Dev 2002; 16: 1568-81.
21. Huang J, Zhou W, Watson AM, Jan YN, Hong Y. Efficient ends-out gene targeting in Drosophila. Genetics 2008; 180: 703-707.
22. Furlong EE, Profitt D, Scott MP. Automated sorting of live transgenic embryos. Nat Biotechnol 2001; 19: 153-156.
23. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008; 322: 881-888.
24. Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 1993; 118: 401-415.
25. Dietzl G, Chen D, Schnorrer F, Su KC, Barinova Y, Fellner M, et al. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 2007; 448: 151-156.
26. McGuire SE, Le PT, Osborn AJ, Matsumoto K, Davis RL. Spatiotemporal rescue of memory dysfunction in Drosophila. Science 2003; 302: 1765-1768.
27. McGuire SE, Roman G, Davis RL. Gene expression systems in Drosophila: a synthesis of time and space. Trends Genet 2004; 20: 384-931.
28. Han DD, Stein D, Stevens LM. Investigating the function of follicular subpopulations during Drosophila oogenesis through hormone-dependent enhancer-targeted cell ablation. Development 2000; 127: 573-83.
29. Osterwalder T, Yoon KS, White BH, Keshishian H. A conditional tissue-specific transgene expression system using inducible GAL4. Proc Natl Acad Sci USA 2001; 98: 12596-12601.
30. Roman G, Endo K, Zong L, Davis RL. P[Switch], a system for spatial and temporal control of gene expression in Drosophila melanogaster. Proc Natl Acad Sci USA 2001; 98: 12602-12607.
31. Stebbins MJ, Urlinger S, Byrne G, Bello B, Hillen W, Yin JC. Tetracycline-inducible systems for Drosophila. Proc Natl Acad Sci USA 2001; 98: 10775-10780.
32. Golic KG, Lindquist S. The FLP recombinase of yeast catalyzes site-specific recombination in the Drosophila genome. Cell 1989; 59: 499-509.
33. Xu T, Rubin GM. Analysis of genetic mosaics in developing and adult Drosophila tissues. Development 1993; 117: 1223-1237.
34. Lee T, Luo L. Mosaic analysis with a repressible cell marker for studies of gene function in neuronal morphogenesis. Neuron 1999; 22: 451-461.
35. Fortini ME, Artavanis-Tsakonas S. The suppressor of hairless protein participates in notch receptor signaling. Cell 1994; 79: 273-282.
36. Simon MA, Bowtell DD, Dodson GS, Laverty TR, Rubin GM. Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. Cell 1991; 67: 701-716.
37. Verheyen EM, Purcell KJ, Fortini ME, Artavanis-Tsakonas S. Analysis of dominant enhancers and suppressors of activated Notch in Drosophila. Genetics 1996; 144: 1127-1141.
38. Dickson BJ, van der Straten A, Dominguez M, Hafen E. Mutations Modulating Raf signaling in Drosophila eye development. Genetics 1996; 142: 163-171.
39. Bier E. Drosophila, the golden bug, emerges as a tool for human genetics. Nat Rev Genet 2005; 6: 9-23.
40. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006; 5: 993-996.
41. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
42. Eggert US, Kiger AA, Richter C, Perlman ZE, Perrimon N, Mitchison TJ, Field CM. Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol 2004; 2: 379.
43. Aroian RV, Koga M, Mendel JE, Ohshima Y, Sternberg PW. The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily. Nature 1990; 348: 693-699.
44. Han M, Sternberg PW. let-60, a gene that specifies cell fates during C. elegans vulval induction, encodes a ras protein. Cell 1990; 63: 921-931.
45. Brumby AM, Richardson HE. Using Drosophila melanogaster to map human cancer pathways. Nat Rev Cancer 2005; 5: 626-639.
46. Jang AC, Starz-Gaiano M, Montell DJ. Modeling migration and metastasis in Drosophila. J Mammary Gland Biol Neoplasia 2007; 12: 103-114.
47. Pagliarini RA, Xu T. A genetic screen in Drosophila for metastatic behavior. Science 2003; 302: 1227-1231.
48. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997; 278: 1064-1068.
49. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, Xie XJ, White MA. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007; 446: 815-819.
50. Vidal M, Cagan RL. Drosophila models for cancer research. Curr Opin Genet Dev 2006; 16: 10-16.
51. McGuire SE, Deshazer M, Davis RL. Thirty years of olfactory learning and memory research in Drosophila melanogaster. Prog Neurobiol 2005; 76: 328-347.
52. Greenspan RJ, Ferveur JF. Courtship in Drosophila. Annu Rev Genet 2000; 34: 205-232.
53. Dickson BJ. Wired for sex: the neurobiology of Drosophila mating decisions. Science 2008; 322: 904-909.
54. Mehren JE, Ejima A, Griffith LC. Unconventional sex: fresh approaches to courtship learning. Curr Opin Neurobiol 2004; 14: 745-750.
55. Cauchi RJ, van den Heuvel M. The fly as a model for neurodegenerative diseases: is it worth the jump? Neurodegener Dis 2006; 3: 338-356.
56. Bilen J, Bonini NM. Drosophila as a model for human neurodegenerative disease. Annu Rev Genet 2005; 39: 153-171.
57. Marsh JL, Thompson LM. Drosophila in the study of neurodegenerative disease. Neuron 2006; 52: 169-178.
58. Morrissette DA, Parachikova A, Green KN, Laferla FM. Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem 2008.
59. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 2000; 924: 17-25.
60. Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci 1993; 695: 144-148.
61. De Strooper B. Aph-1, Pen-2 and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 2003; 38: 9-12.
62. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376: 775-778.
63. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-760.
64. Nishimura M, Yu G, St. George-Hyslop PH. Biology of presenilins as causative molecules for Alzheimer disease. Clin Genet 1999; 55: 219-225.
65. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, Bird TD, Schellenberg GD. A familial Alzheimer's disease locus on chromosome 1. Science 1995; 269: 970-973.
66. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 1963; 197: 192-193.
67. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001; 293: 711-714.
68. Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Malester B, Hutton M, Adamson J, Goedert M, Burki K, Davies P. Characterization of pathology in transgenic mice overexpressing human genomic and cDNA tau transgenes. Neurobiol Dis 2000; 7: 87-98.
69. Seitz A, Kojima H, Oiwa K, Mandelkow EM, Song YH, Mandelkow E. Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J 2002; 21: 4896-4905.
70. Wagner U, Utton M, Gallo JM, Miller CC. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 1996; 109: 1537-1543.
71. De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008; 31: 151-173.
72. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, Geschwind DH. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002; 34: 509-519.
73. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
74. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
75. Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M. A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. Mol Cell Neurosci 2004; 26: 365-375.
76. Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc Natl Acad Sci USA 2004; 101: 6623-6628.
77. Greeve I, Kretzschmar D, Tschape JA, Beyn A, Brellinger C, Schweizer M, Nitsch RM, Reifegerste R. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci 2004; 24: 3899-3906.
78. Cao W, Song HJ, Gangi T, Kelkar A, Antani I, Garza D, Konsolaki M. Identification of novel genes that modify phenotypes induced by Alzheimer's beta-amyloid overexpression in Drosophila. Genetics 2008; 178: 1457-1471.
79. Shen J, Kelleher RJ, 3rd. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 2007; 104: 403-409.
80. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 2004; 114: 1624-34.
81. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631-639.
82. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791.
83. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004; 44: 181-193.
84. Ye Y, Lukinova N, Fortini ME. Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants. Nature 1999; 398: 525-529.
85. Lewy F. Paralysis agitans. Part I: Pathologische Anatomie. In: Lewandowsky M, ed. Handbuch der Neurologie,Vol III, spezNeurol II. Berlin: Springer 1912; 920-933.
86. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
87. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
88. Whitworth AJ, Wes PD, Pallanck LJ. Drosophila models pioneer a new approach to drug discovery for Parkinson's disease. Drug Discov Today 2006; 11: 119-126.
89. Hudson G, Schaefer AM, Taylor RW, Tiangyou W, Gibson A, Venables G, et al. Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism. Arch Neurol 2007; 64: 553-557.
90. Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA, et al. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology 2008; 71: 28-34.
91. Whitworth AJ, Lee JR, Ho VM, Flick R, Chowdhury R, McQuibban GA. Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin. Dis Model Mech 2008; 1: 168-174.
92. DeStefano AL, Latourelle J, Lew MF, Suchowersky O, Klein C, Golbe LI, et al. Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet 2008; 124: 95-99.
93. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000; 404: 394-398.
94. Park SS, Lee D. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures. Eur J Neurosci 2006; 23: 2908-2914.
95. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002; 295: 865-868.
96. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007; 317: 516-519.
97. Langley B, Gensert JM, Beal MF, Ratan RR. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord 2005; 4: 41-50.
98. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 2003; 100: 4078-4083.
99. Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, Zhou Y, et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004; 131: 2183-2194.
100. Shao J, Diamond MI. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet 2007; 16: 115-123.
101. Branco J, Al-Ramahi I, Ukani L, Perez AM, Fernandez-Funez P, Rincon-Limas D, Botas J. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases. Hum Mol Genet 2008; 17: 376-390.
102. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000; 23: 217-247.
103. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008; 7: 854-868.
104. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001; 413: 739-743.
105. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, Marsh JL. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 2008; 17: 3767-3775.
106. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36: 585-595.
107. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 2007; 3: 82.
108. Bilen J, Bonini NM. Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila. PLoS Genet 2007; 3: 1950-1964.
109. Roeleveld N, Zielhuis GA, Gabreels F. The prevalence of mental retardation: a critical review of recent literature. Dev Med Child Neurol 1997; 39: 125-132.
110. Inlow JK, Restifo LL. Molecular and comparative genetics of mental retardation. Genetics 2004; 166: 835-881.
111. McLaren J, Bryson SE. Review of recent epidemiological studies of mental retardation: prevalence, associated disorders and etiology. Am J Ment Retard 1987; 92: 243-254.
112. Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008; 60: 201-214.
113. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 2002; 99: 7746-7750.
114. Wan L, Dockendorff TC, Jongens TA, Dreyfuss G. Characterization of dFMR1, a Drosophila melanogaster homolog of the fragile X mental retardation protein. Mol Cell Biol 2000; 20: 8536-8547.
115. Zhang YQ, Bailey AM, Matthies HJ, Renden RB, Smith MA, Speese SD, et al. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell 2001; 107: 591-603.
116. Gao FB. Understanding fragile X syndrome: insights from retarded flies. Neuron 2002; 34: 859-862.
117. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, et al. Pharmacological rescue of synaptic plasticity, courtship behavior and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005; 45: 753-764.
118. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005; 49: 1053-1066.
119. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF. Correction of fragile X syndrome in mice. Neuron 2007; 56: 955-962.
120. Wu Y, Bolduc FV, Bell K, Tully T, Fang Y, Sehgal A, Fischer JA. A Drosophila model for Angelman syndrome. Proc Natl Acad Sci USA 2008; 105: 12399-12404.
121. Greene JC, Whitworth AJ, Andrews LA, Parker TJ, Pallanck LJ. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum Mol Genet 2005; 14: 799-811.
122. Tully T, Bourtchouladze R, Scott R, Tallman J. Targeting the CREB pathway for memory enhancers. Nat Rev Drug Discov 2003; 2: 267-277.
123. Fishman MC, Porter JA. Pharmaceuticals: a new grammar for drug discovery. Nature 2005; 437: 491-493.